Position in NVO
as of Jun 30, 2026
· filed Aug 17, 2026
Position Value
$2,290,477
-$1,331,088 QoQ
Shares Held
47,778
-51.5% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#355
of 1,348 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in NVO Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026CAPSTONE INVESTMENT ADVISORS, LLC holds $11,314,373 across 8 Drug Manufacturers - General names. NVO ranks #2 (20.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PFE |
Pfizer Inc
|
126,497 | $3,046,047 | |
| 2 | NVO |
Novo Nordisk A S
This page
|
47,778 | $2,290,477 | |
| 3 | GILD |
Gilead Sciences, Inc.
|
14,121 | $1,784,047 | |
| 4 | LLY |
ELI LILLY & Co
|
1,477 | $1,771,558 | |
| 5 | BMY |
Bristol Myers Squibb Co
|
15,232 | $877,667 | |
| 6 | JNJ |
Johnson & Johnson
|
2,792 | $709,084 | |
| 7 | MRK |
Merck & Co., Inc.
|
4,009 | $515,156 | |
| 8 | ABBV |
AbbVie Inc.
|
1,273 | $320,337 |
All Filings in NVO
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,290,477 | 47,778 | Shares | Defined | 2026-08-17 | |
| 2026-03-31 | $3,621,565 | 98,546 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $494,502 | 9,719 | Shares | Defined | 2026-02-17 | |
| 2025-09-30 | $204,480 | 3,685 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $10,353,000 | 150,000 | Shares | Defined | 2025-08-14 | |
| No filing history on record for this holder in this stock. | ||||||